Cargando…
Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury
Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and tel...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147195/ https://www.ncbi.nlm.nih.gov/pubmed/25197586 http://dx.doi.org/10.1155/2014/308729 |
_version_ | 1782332395690655744 |
---|---|
author | Callau Monje, David Braun, Niko Latus, Joerg Amann, Kerstin Alscher, Mark Dominik Kimmel, Martin |
author_facet | Callau Monje, David Braun, Niko Latus, Joerg Amann, Kerstin Alscher, Mark Dominik Kimmel, Martin |
author_sort | Callau Monje, David |
collection | PubMed |
description | Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and telaprevir, the standard therapy for patients with genotype 1 changed. In patients with acute kidney injury (AKI) these therapies are not approved and have so far not been evaluated in studies. Case Report. In April 2012, a 58-year-old female was admitted due to a cryoglobulin-positive chronic HCV infection which had been treated with interferon and ribavirin. Currently, the patient was admitted because of severe complications with an acute kidney injury. We treated our patient successfully with a boceprevir based triple therapy. Conclusion. Limited data suggests that a therapy with ribavirin in patients with AKI seems to be safe under close monitoring. Our patient was treated successfully with a protease inhibitor based triple therapy. Nevertheless, it is necessary to plan an interventional study to evaluate the exact risk-benefit profile of triple therapy regimens in patients with AKI and hepatitis C. |
format | Online Article Text |
id | pubmed-4147195 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-41471952014-09-07 Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury Callau Monje, David Braun, Niko Latus, Joerg Amann, Kerstin Alscher, Mark Dominik Kimmel, Martin Case Rep Nephrol Case Report Introduction. The HCV infection is a common disease with many chronically infected patients worldwide. So far, the standard therapy of a chronic HCV infection consisted of interferon as single therapy or in combination with ribavirin. After approval of the two protease inhibitors, boceprevir and telaprevir, the standard therapy for patients with genotype 1 changed. In patients with acute kidney injury (AKI) these therapies are not approved and have so far not been evaluated in studies. Case Report. In April 2012, a 58-year-old female was admitted due to a cryoglobulin-positive chronic HCV infection which had been treated with interferon and ribavirin. Currently, the patient was admitted because of severe complications with an acute kidney injury. We treated our patient successfully with a boceprevir based triple therapy. Conclusion. Limited data suggests that a therapy with ribavirin in patients with AKI seems to be safe under close monitoring. Our patient was treated successfully with a protease inhibitor based triple therapy. Nevertheless, it is necessary to plan an interventional study to evaluate the exact risk-benefit profile of triple therapy regimens in patients with AKI and hepatitis C. Hindawi Publishing Corporation 2014 2014-08-14 /pmc/articles/PMC4147195/ /pubmed/25197586 http://dx.doi.org/10.1155/2014/308729 Text en Copyright © 2014 David Callau Monje et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Callau Monje, David Braun, Niko Latus, Joerg Amann, Kerstin Alscher, Mark Dominik Kimmel, Martin Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury |
title | Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury |
title_full | Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury |
title_fullStr | Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury |
title_full_unstemmed | Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury |
title_short | Successful Antiviral Triple Therapy in a Longstanding Refractory Hepatitis C Virus Infection with an Acute Kidney Injury |
title_sort | successful antiviral triple therapy in a longstanding refractory hepatitis c virus infection with an acute kidney injury |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147195/ https://www.ncbi.nlm.nih.gov/pubmed/25197586 http://dx.doi.org/10.1155/2014/308729 |
work_keys_str_mv | AT callaumonjedavid successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury AT braunniko successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury AT latusjoerg successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury AT amannkerstin successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury AT alschermarkdominik successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury AT kimmelmartin successfulantiviraltripletherapyinalongstandingrefractoryhepatitiscvirusinfectionwithanacutekidneyinjury |